From: Clinical significance of NUCB2 mRNA expression in prostate cancer
 |  | NUCB2 mRNA expression |  | ||
---|---|---|---|---|---|
Variable | Group | High | Low | Total | P value |
Age | Â | Â | Â | Â | 0.100 |
 | <70 | 43 (44.3%) | 54 (55.7%) | 97 |  |
 | ≥70 | 47 (56.6%) | 36 (43.4%) | 83 |  |
Lymph node metastasis | Â | Â | Â | Â | 0.022 |
 | Negtive | 77 (47.2%) | 86 (52.8%) | 163 |  |
 | Positive | 13 (76.5%) | 4 (23.5%) | 17 |  |
Surgical margin status | Â | Â | Â | Â | 0.578 |
 | Negtive | 82 (49.4%) | 84 (50.6%) | 166 |  |
 | Positive | 8 (57.1%) | 6 (42.9%) | 14 |  |
Seminal vesicle invasion | Â | Â | Â | Â | 0.202 |
 | Negtive | 67 (46.2%) | 78 (53.8%) | 145 |  |
 | Positive | 23 (65.7%) | 12 (34.3%) | 35 |  |
Clinical stage | Â | Â | Â | Â | 0.880 |
 | T1 | 52 (50.5%) | 51 (49.5%) | 103 |  |
 | T2/T3 | 38 (49.4%) | 39 (50.6%) | 77 |  |
Preoperative PSA | Â | Â | Â | Â | 0.004 |
 | <4 | 1 (20%) | 4 (80%) | 5 |  |
 | 4-10 | 23 (35.9) | 41 (64.1%) | 64 |  |
 | >10 | 66 (59.5%) | 45 (40.5%) | 111 |  |
Gleason score | Â | Â | Â | Â | Â |
 | <7 | 35 (35.4%) | 64 (64.6%) | 99 | <0.001 |
 | 7 | 19 (55.9%) | 15 (44.1%) | 34 |  |
 | >7 | 36 (76.6%) | 11 (23.4%) | 47 |  |
Angiolymphatic invasion | Â | Â | Â | Â | 0.004 |
 | Negtive | 66 (44.9%) | 81 (55.1%) | 147 |  |
 | Positive | 24 (72.7%) | 9 (27.3%) | 33 |  |